China Healthwise Holdings Limited (HKG:0348)
Hong Kong
· Delayed Price · Currency is HKD 0.150
-0.005 (-3.23%)
Mar 17, 2025, 11:09 AM HKT
China Healthwise Holdings Revenue
China Healthwise Holdings had revenue of 60.93M HKD in the half year ending June 30, 2024, a decrease of -20.11%. This brings the company's revenue in the last twelve months to 126.42M, down -13.77% year-over-year. In the year 2023, China Healthwise Holdings had annual revenue of 146.32M with 3.00% growth.
Revenue (ttm)
126.42M
Revenue Growth
-13.77%
P/S Ratio
0.91
Revenue / Employee
1.58M
Employees
100
Market Cap
115.57M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 146.32M | 4.26M | 3.00% |
| Dec 31, 2022 | 142.06M | -28.02M | -16.48% |
| Dec 31, 2021 | 170.08M | 32.23M | 23.38% |
| Dec 31, 2020 | 137.85M | -6.02M | -4.19% |
| Dec 31, 2019 | 143.88M | -307.74M | -68.14% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.00B |
| JD Health International | 61.89B |
| WuXi Biologics | 18.39B |
| Alibaba Health Information Technology | 31.39B |
| Innovent Biologics | 8.01B |
| Akeso | 2.01B |
| Sino Biopharmaceutical | 29.86B |